유방 영상 진단 시장 규모·점유율 및 동향 분석 보고서 : 기술별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Breast Imaging Market Summary

The global breast imaging market size was estimated at USD 5.88 billion in 2025 and is projected to reach USD 12.03 billion by 2033, growing at a CAGR of 9.7% from 2026 to 2033. Factors such as the rising prevalence of breast cancer, technological breakthroughs in the domain of breast imaging, and investment from several organizations in breast cancer screening programs drive the breast imaging market.

According to the World Cancer Research Fund (WCRF), by 2030, the number of cases of breast cancer is expected to reach about 2.1 million globally. According to a new report from the International Agency for Research on Cancer (IARC), breast cancer cases are expected to increase by 38 percent globally by 2050, with annual deaths from the disease projected to rise by 68 percent. This aspect is expected to contribute to the growth of the breast imaging market over the forecast period.

The growing prevalence of breast cancer and other breast-related abnormalities is expected to drive the expansion of the breast imaging market significantly. According to data published by the National Breast Cancer Foundation, Inc. in June 2025, approximately 1 in 8 women in the U.S. is expected to be diagnosed with breast cancer during their lifetime. In addition, projections from the International Agency for Research on Cancer estimate a 27.8% increase in breast cancer incidence in the U.S. between 2022 and 2050, with cases expected to reach approximately 350,693 by 2050. This substantial rise in cancer cases is anticipated to fuel the demand for breast magnetic resonance imaging procedures across the country.

Technological advancements are driving the growth of the breast imaging market, supported by increasing demand for earlier and more accurate cancer detection. Innovations such as molecular breast imaging, AI-assisted diagnostics, and enhanced breast imaging displays are improving clinical confidence and reducing interpretation challenges. As healthcare providers prioritize precision medicine and screening efficiency, these advanced tools continue to accelerate adoption and shape the future of breast cancer detection and care.

Widespread research in the development of hybrid imaging systems provides high growth opportunities and also aids the market growth. Recent developments in imaging technology have completely revolutionized the nature of treatment and how it is approached. To view the metabolic data and anatomical characteristics of the organs, it has become more crucial to combine imaging methods such as CT scans, MRIs, PET, and others. Furthermore, the quality of breast pictures, patient comfort, and patient dose have all been enhanced by these integrated imaging modalities. Thereby, owing to these advantages, manufacturers across the globe are concentrating more on the introduction of new products to improve the sensitivity and precision of breast cancer diagnostics. For instance, in February 2025, DeepHealth plans to introduce its Diagnostic Suite to the European market, offering a next-generation PACS system with a unified, workflow-optimized radiology workspace. The company also aims to expand access to SmartMammo, its AI-driven end-to-end mammography diagnostic solution, further integrating AI-enabled detection and clinical decision support into routine imaging workflows.

Global Breast Imaging Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global breast imaging market report based on technology, end use, and region:

• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Ionizing
  • Full-field Digital Mammography
  • Analog Mammography
  • Positron Emission Mammography
  • Electric Impedance Tomography
  • Cone-beam Computed Tomography
  • Positron Emission Tomography & Computed Tomography
  • 3D Breast Tomosynthesis
  • MBI/BSGI
• Non Ionizing
  • MRI
  • Thermography
  • Ultrasound
  • Optical Imaging
  • Automated Whole-Breast Ultrasound
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Breast Care Centers
• Diagnostic Imaging Centers
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Technology
  • 1.1.2. End use
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Breast Imaging Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growing prevalence of breast cancer
    • 3.2.1.2. Technological advancements in the field of breast imaging
    • 3.2.1.3. Investments and initiatives from various organizations in breast cancer screening campaigns
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Risk of adverse effects from radiation exposure
    • 3.2.2.2. High cost of imaging systems
  • 3.2.3. Market opportunity analysis
    • 3.2.3.1. Growing number of clinical trials
    • 3.2.3.2. Growing awareness of early detection
  • 3.2.4. Market challenge analysis
    • 3.2.4.1. Shortage of trained radiologists
• 3.3. Breast Imaging Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal Landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological landscape

Chapter 4. Breast Imaging Market: Technology Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Breast Imaging Market Technology Movement Analysis
• 4.3. Global Breast Imaging Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
• 4.4. Ionizing
  • 4.4.1. Ionizing market estimates and forecasts for 2021 to 2033 (USD Million)
  • 4.4.2. Full-Field Digital Mammography
    • 4.4.2.1. Full-field digital mammography market estimates and forecasts for 2021 to 2033 (USD Million)
  • 4.4.3. Analog Mammography
    • 4.4.3.1. Analog mammography market estimates and forecasts for 2021 to 2033 (USD Million)
  • 4.4.4. Positron Emission Mammography
    • 4.4.4.1. Positron emission mammography market estimates and forecasts for 2021 to 2033 (USD Million)
  • 4.4.5. Electric Impedance Tomography
    • 4.4.5.1. Electric impedance tomography market estimates and forecasts for 2021 to 2033 (USD Million)
  • 4.4.6. Cone-Beam Computed Tomography
    • 4.4.6.1. Cone-beam computed tomography market estimates and forecasts for 2021 to 2033 (USD Million)
  • 4.4.7. Positron Emission Tomography & Computed Tomography
    • 4.4.7.1. Positron emission tomography & computed tomography market estimates and forecasts for 2021 to 2033 (USD Million)
  • 4.4.8. 3D Breast Tomosynthesis
    • 4.4.8.1. 3D breast tomosynthesis market estimates and forecasts for 2021 to 2033 (USD Million)
  • 4.4.9. MBI/BSGI
    • 4.4.9.1. MBI/BSGI market estimates and forecasts for 2021 to 2033 (USD Million)
• 4.5. Non Ionizing
  • 4.5.1. Non Ionizing market estimates and forecasts for 2021 to 2033 (USD Million)
  • 4.5.2. MRI
    • 4.5.2.1. MRI market estimates and forecasts for 2021 to 2033 (USD Million)
  • 4.5.3. Thermography
    • 4.5.3.1. Thermography market estimates and forecasts for 2021 to 2033 (USD Million)
  • 4.5.4. Ultrasound
    • 4.5.4.1. Ultrasound market estimates and forecasts for 2021 to 2033 (USD Million)
  • 4.5.5. Optical Imaging
    • 4.5.5.1. Optical imaging market estimates and forecasts for 2021 to 2033 (USD Million)
  • 4.5.6. Automated Whole-Breast Ultrasound
    • 4.5.6.1. Automated whole-breast ultrasound market estimates and forecasts for 2021 to 2033 (USD Million)

Chapter 5. Breast Imaging: End Use Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Breast Imaging Market End Use Movement Analysis
• 5.3. Global Breast Imaging Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals market estimates and forecasts for 2021 to 2033 (USD Million)
• 5.5. Diagnostic Imaging Centers
  • 5.5.1. Diagnostic imaging centers market estimates and forecasts for 2021 to 2033 (USD Million)
• 5.6. Breast Care Centers
  • 5.6.1. Breast care centers market estimates and forecasts for 2021 to 2033 (USD Million)

Chapter 6. Breast Imaging Market: Regional Estimates & Trend Analysis

• 6.1. Regional Dashboard
• 6.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
• 6.3. North America
  • 6.3.1. Market estimates and forecast, 2021 - 2033 (Revenue, USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Competitive scenario
    • 6.3.2.3. Regulatory framework
    • 6.3.2.4. Reimbursement scenario
    • 6.3.2.5. U.S. market estimates and forecasts, 2021 - 2033
  • 6.3.3. Canada
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Competitive scenario
    • 6.3.3.3. Regulatory framework
    • 6.3.3.4. Reimbursement scenario
    • 6.3.3.5. Canada market estimates and forecasts, 2021 - 2033
  • 6.3.4. Mexico
    • 6.3.4.1. Key country dynamics
    • 6.3.4.2. Competitive scenario
    • 6.3.4.3. Regulatory framework
    • 6.3.4.4. Reimbursement scenario
    • 6.3.4.5. Mexico market estimates and forecasts, 2021 - 2033
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Competitive scenario
    • 6.4.1.3. Regulatory framework
    • 6.4.1.4. Reimbursement scenario
    • 6.4.1.5. UK market estimates and forecasts, 2021 - 2033
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Competitive scenario
    • 6.4.2.3. Regulatory framework
    • 6.4.2.4. Reimbursement scenario
    • 6.4.2.5. Germany market estimates and forecasts, 2021 - 2033
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Competitive scenario
    • 6.4.3.3. Regulatory framework
    • 6.4.3.4. Reimbursement scenario
    • 6.4.3.5. France market estimates and forecasts, 2021 - 2033
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Competitive scenario
    • 6.4.4.3. Regulatory framework
    • 6.4.4.4. Reimbursement scenario
    • 6.4.4.5. Italy market estimates and forecasts, 2021 - 2033
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Competitive scenario
    • 6.4.5.3. Regulatory framework
    • 6.4.5.4. Reimbursement scenario
    • 6.4.5.5. Spain market estimates and forecasts, 2021 - 2033
  • 6.4.6. Denmark
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Competitive scenario
    • 6.4.6.3. Regulatory framework
    • 6.4.6.4. Reimbursement scenario
    • 6.4.6.5. Denmark market estimates and forecasts, 2021 - 2033
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Competitive scenario
    • 6.4.7.3. Regulatory framework
    • 6.4.7.4. Reimbursement scenario
    • 6.4.7.5. Sweden market estimates and forecasts, 2021 - 2033
  • 6.4.8. Norway
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Competitive scenario
    • 6.4.8.3. Regulatory framework
    • 6.4.8.4. Reimbursement scenario
    • 6.4.8.5. Norway market estimates and forecasts, 2021 - 2033
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Competitive scenario
    • 6.5.1.3. Regulatory framework
    • 6.5.1.4. Reimbursement scenario
    • 6.5.1.5. Japan market estimates and forecasts, 2021 - 2033
  • 6.5.2. India
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Competitive scenario
    • 6.5.2.3. Regulatory framework
    • 6.5.2.4. Reimbursement scenario
    • 6.5.2.5. India market estimates and forecasts, 2021 - 2033
  • 6.5.3. China
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Competitive scenario
    • 6.5.3.3. Regulatory framework
    • 6.5.3.4. Reimbursement scenario
    • 6.5.3.5. China market estimates and forecasts, 2021 - 2033
  • 6.5.4. South Korea
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Competitive scenario
    • 6.5.4.3. Regulatory framework
    • 6.5.4.4. Reimbursement scenario
    • 6.5.4.5. South Korea market estimates and forecasts, 2021 - 2033
  • 6.5.5. Australia
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Competitive scenario
    • 6.5.5.3. Regulatory framework
    • 6.5.5.4. Reimbursement scenario
    • 6.5.5.5. Australia market estimates and forecasts, 2021 - 2033
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Competitive scenario
    • 6.5.6.3. Regulatory framework
    • 6.5.6.4. Reimbursement scenario
    • 6.5.6.5. Thailand market estimates and forecasts, 2021 - 2033
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Competitive scenario
    • 6.6.1.3. Regulatory framework
    • 6.6.1.4. Reimbursement scenario
    • 6.6.1.5. Brazil market estimates and forecasts, 2021 - 2033
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Competitive scenario
    • 6.6.2.3. Regulatory framework
    • 6.6.2.4. Reimbursement scenario
    • 6.6.2.5. Argentina market estimates and forecasts, 2021 - 2033
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Competitive scenario
    • 6.7.1.3. Regulatory framework
    • 6.7.1.4. Reimbursement scenario
    • 6.7.1.5. South Africa market estimates and forecasts, 2021 - 2033
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Competitive scenario
    • 6.7.2.3. Regulatory framework
    • 6.7.2.4. Reimbursement scenario
    • 6.7.2.5. Saudi Arabia market estimates and forecasts, 2021 - 2033
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Competitive scenario
    • 6.7.3.3. Regulatory framework
    • 6.7.3.4. Reimbursement scenario
    • 6.7.3.5. UAE market estimates and forecasts, 2021 - 2033
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Competitive scenario
    • 6.7.4.3. Regulatory framework
    • 6.7.4.4. Reimbursement scenario
    • 6.7.4.5. Kuwait market estimates and forecasts, 2021 - 2033

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
  • 7.2.1. Innovators
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Global Key company market share analysis, 2024
  • 7.3.4. GE HealthCare
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Siemens Healthineers
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Philips Healthcare
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Hologic, Inc.
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Fujifilm Holdings Corp.
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. SonoCine, Inc.
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Toshiba Corporation (Canon Inc.)
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Dilon Technologies, Inc.
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. SonoCine, Inc.
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. Aurora Imaging Technology, Inc.
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Product benchmarking
    • 7.3.13.4. Strategic initiatives
• 7.4. Heat Map Analysis/ Company Market Position Analysis
• 7.5. Estimated Company Market Share Analysis, 2025
• 7.6. List of Other Key Market Players